Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
Type:
Application
Filed:
December 8, 2003
Publication date:
June 23, 2005
Applicant:
Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc.
Inventors:
Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan
Abstract: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
Type:
Application
Filed:
December 8, 2003
Publication date:
June 2, 2005
Applicant:
Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc.
Inventors:
Yaron Ilan, Elazar Rabbani, Dean Engelhardt, Israel Gotsman, James Donegan
Abstract: Procedures and compositions for forming and stabilizing non stable branch migrated oligo- and polydeoxynucleotides utilizing a displacer which is either single stranded or partially double stranded and hybridized to a linker strand. The displacer may contain one or more modified nucleotides.
Type:
Application
Filed:
July 3, 2001
Publication date:
March 10, 2005
Applicant:
Enzo Therapeutics, Inc.
Inventors:
James Wetmur, Robin Quartin, Dean Engelhardt
Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.
Type:
Application
Filed:
December 10, 2003
Publication date:
September 2, 2004
Applicant:
Enzo Therapeutics, Inc.
Inventors:
Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.
Type:
Application
Filed:
December 10, 2003
Publication date:
September 2, 2004
Applicant:
Enzo Therapeutics, Inc.
Inventors:
Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.
Type:
Application
Filed:
December 10, 2003
Publication date:
September 2, 2004
Applicant:
Enzo Therapeutics, Inc.
Inventors:
Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
Abstract: Novel immune modulating processes are provided in which the immunological state of a subject including mature subjects, mammals and humans, are down regulated in a selective manner, and as a subset in a dominant manner. The novel immunological state termed SIDR for selective immune down regulation is usefully applied to the immunological modulation or regulation of gene delivery components, artificially expressed genes, gene delivery systems and expression products of artificially introduced genes by such delivery systems, and infectious agents. SIDR is also useful when combined with other immune modulating treatments such as general immune suppression and anti-apoptosis. SIDR may also be used to selectively down regulate the immune response system of a subject to a wide variety of noncellular immunogenic components and to native antigens. Other processes for producing immune suppression by administering macromolecules or compounds to a subject so as to obtain or effect SIDR are also provided.
Type:
Application
Filed:
March 4, 2003
Publication date:
February 5, 2004
Applicant:
Enzo Therapeutics, Inc
Inventors:
Jayanta Roy-Chowdhury, Yaron Ilan, Elazar Rabbani, Dean L. Engelhardt
Abstract: Novel immune modulating processes are provided in which the imunological state of a subject including mature subjects, mammals and humans, are down regulated in a selective manner, and as a subset in a dominant manner. The novel immunological state termed SIDR for selective immune down regulation is usefully applied to the immunological modulation or regulation of gene delivery components, artificially expressed genes, gene delivery systems and expression products of artificially introduced genes by such delivery systems, and infectious agents. SIDR is also useful when combined with other immune modulating treatments such as general immune suppression and anti-apoptosis. SIDR may also be used to selectively down regulate the immune response system of a subject to a wide variety of noncellular immunogenic components and to native antigens. Other processes for producing immune suppression by administering macromolecules or compounds to a subject so as to obtain or effect SIDR are also provided.
Type:
Application
Filed:
March 4, 2003
Publication date:
February 5, 2004
Applicant:
Enzo Therapeutics, Inc
Inventors:
Jayanta Roy-Chowdhury, Yaron Ilan, Elazar Rabbani, Dean L. Engelhardt
Abstract: Novel immune modulating processes are provided in which the imunological state of a subject including mature subjects, mammals and humans, are down regulated in a selective manner, and as a subset in a dominant manner. The novel immunological state termed SIDR for selective immune down regulation is usefully applied to the immunological modulation or regulation of gene delivery components, artificially expressed genes, gene delivery systems and expression products of artificially introduced genes by such delivery systems, and infectious agents. SIDR is also useful when combined with other immune modulating treatments such as general immune suppression and anti-apoptosis. SIDR may also be used to selectively down regulate the immune response system of a subject to a wide variety of noncellular immunogenic components and to native antigens. Other processes for producing immune suppression by administering macromolecules or compounds to a subject so as to obtain or effect SIDR are also provided.
Type:
Application
Filed:
March 12, 2003
Publication date:
September 11, 2003
Applicant:
Enzo Therapeutics, Inc.
Inventors:
Jayanta Roy-Chowdhury, Yaron Ilan, Elazar Rabbani, Dean L. Engelhardt
Abstract: Procedures and compositions for forming and stabilizing non stable branch migrated oligo- and polydeoxynucleotides utilizing a displacer which is either single stranded or partially double stranded and hybridized to a linker strand. The displacer may contain one or more modified nucleotides.
Type:
Grant
Filed:
August 31, 1999
Date of Patent:
March 19, 2002
Assignee:
Enzo Therapeutics, Inc.
Inventors:
James G. Wetmur, Robin S. Quartin, Dean L. Engelhardt
Abstract: Procedures and compositions for forming and stabilizing non stable branch migrated oligo- and polydeoxynucleotides utilizing a displacer which is either single stranded or partially double stranded and hybridized to a linker strand. The displacer may contain one or more modified nucleotides.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 28, 1999
Assignee:
Enzo Therapeutics, Inc.
Inventors:
James G. Wetmur, Robin S. Quartin, Dean L. Engelhardt